Literature DB >> 26450994

A SNP in the Immunoregulatory Molecule CTLA-4 Controls mRNA Splicing In Vivo but Does Not Alter Diabetes Susceptibility in the NOD Mouse.

Fabian Jakubczik1, Ken Jones2, Jennifer Nichols2, William Mansfield3, Anne Cooke1, Nick Holmes4.   

Abstract

CTLA-4 is a critical "checkpoint" regulator in autoimmunity. Variation in CTLA-4 isoform expression has been linked to type 1 diabetes development in human and NOD mouse studies. In the NOD mouse, a causative link between increased expression of the minor isoform ligand-independent CTLA-4 and a reduction in diabetes has become widely accepted. Altered splicing of CTLA-4 has been attributed to a single nucleotide polymorphism (SNP) in Ctla4 exon2 (e2_77A/G). To investigate this link, we have used NOD embryonic stem (ES) cells to generate a novel NOD transgenic line with the 77A/G SNP. This strain phenocopies the increase in splicing toward the liCTLA4 isoform seen in B10 Idd5.1 mice. Crucially, the SNP does not alter the spontaneous incidence of diabetes, the incidence of cyclophosphamide-induced diabetes, or the activation of diabetogenic T-cell receptor transgenic CD4(+) T cells after adoptive transfer. Our results show that one or more of the many other linked genetic variants between the B10 and NOD genome are required for the diabetes protection conferred by Idd5.1. With the NOD mouse model closely mimicking the human disease, our data demonstrate that knock-in transgenic mice on the NOD background can test causative mutations relevant in human diabetes.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26450994      PMCID: PMC4693968          DOI: 10.2337/db15-1175

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

1.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

2.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone.

Authors:  K Haskins; M McDuffie
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

3.  An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice.

Authors:  David C Thomas; Richard J Mellanby; Jenny M Phillips; Anne Cooke
Journal:  Immunology       Date:  2007-04-16       Impact factor: 7.397

4.  Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity.

Authors:  Yuko Ikezawa; Masatoshi Nakazawa; Chizuru Tamura; Kazuo Takahashi; Mutsuhiko Minami; Zenro Ikezawa
Journal:  J Dermatol Sci       Date:  2005-08       Impact factor: 4.563

5.  Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Sven Brode; Tim Raine; Paola Zaccone; Anne Cooke
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

6.  An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells.

Authors:  Lalitha Vijayakrishnan; Jacqueline M Slavik; Zsolt Illés; Rebecca J Greenwald; Dan Rainbow; Bernhard Greve; Laurence B Peterson; David A Hafler; Gordon J Freeman; Arlene H Sharpe; Linda S Wicker; Vijay K Kuchroo
Journal:  Immunity       Date:  2004-05       Impact factor: 31.745

7.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

8.  Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse.

Authors:  Linda S Wicker; Giselle Chamberlain; Kara Hunter; Dan Rainbow; Sarah Howlett; Paul Tiffen; Jan Clark; Andrea Gonzalez-Munoz; Anne Marie Cumiskey; Raymond L Rosa; Joanna M Howson; Luc J Smink; Amanda Kingsnorth; Paul A Lyons; Simon Gregory; Jane Rogers; John A Todd; Laurence B Peterson
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes.

Authors:  P Höglund; J Mintern; C Waltzinger; W Heath; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

10.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre.

Authors:  Jasper de Boer; Adam Williams; George Skavdis; Nicola Harker; Mark Coles; Mauro Tolaini; Trisha Norton; Keith Williams; Kathleen Roderick; Alexandre J Potocnik; Dimitris Kioussis
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

View more
  3 in total

Review 1.  Using GWAS to identify novel therapeutic targets for osteoporosis.

Authors:  Olivia L Sabik; Charles R Farber
Journal:  Transl Res       Date:  2016-10-27       Impact factor: 7.012

2.  Defined conditions for propagation and manipulation of mouse embryonic stem cells.

Authors:  Carla Mulas; Tüzer Kalkan; Ferdinand von Meyenn; Harry G Leitch; Jennifer Nichols; Austin Smith
Journal:  Development       Date:  2019-03-26       Impact factor: 6.862

3.  CRISPR-Cas9-Mediated Modification of the NOD Mouse Genome With Ptpn22R619W Mutation Increases Autoimmune Diabetes.

Authors:  Xiaotian Lin; Stephane Pelletier; Sebastien Gingras; Stephanie Rigaud; Christian J Maine; Kristi Marquardt; Yang D Dai; Karsten Sauer; Alberto R Rodriguez; Greg Martin; Sergey Kupriyanov; Ling Jiang; Liping Yu; Douglas R Green; Linda A Sherman
Journal:  Diabetes       Date:  2016-04-26       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.